Care Priorities
/
Cell & Gene Therapy
Care priority · High-cost and complex care

Make rare, high-cost treatment coordination accountable.

Connect the plan’s benefit terms, administrator and payer responsibilities, certified treatment centers and specialty coordination, including any contractually relevant stop-loss notification. No treatment delays, clinical decisions or reimbursement guarantees.

Illustrative governance application
Published market signal
$2M–$3M

approximate cost per patient of the two sickle cell disease gene therapies examined in CMS’s Cell and Gene Therapy Access Model, per its first evaluation report (August 2026).

Limitation: A specific example. It is not a price range for every cell or gene therapy.

Source: CMS Innovation Center, CGT Access Model evaluation ↗

Why it matters to self-funded plans

Cell and gene therapies are rare for any single plan, but each case can involve a certified treatment center, an administrator, a PBM or medical benefit, a stop-loss carrier and months of follow-up. Responsibilities are spread across parties that may not share one record.

Governance helps the plan see who acknowledged what and when, and whether contractual notifications were made.

01 · Sponsor decisions

What the plan may configure

Which benefit terms and administrator responsibilities apply
Which certified treatment centers are presented
Who coordinates specialty referrals and approvals
Which stop-loss notification steps are contractually relevant
Which events return to the plan for review
02 · Existing destinations

Illustrative care destinations

Certified or qualified treatment centers
Specialty case management the plan already uses
The plan’s administrator and PBM processes
Stop-loss carrier notification, where the contract requires it

The treating specialist and standard benefit processes stay available.

03 · Evidence

What partner response and encounter evidence should return

Referral acknowledgment
Approvals recorded
Treatment-center coordination
Episode milestones
Supporting documentation
Claim and contract reconciliation, as permitted
04 · Before deployment

What must be validated first

Benefit terms, administrator agreements and stop-loss provisions are reviewed
Each destination agrees to acknowledge referrals within set timelines
Data-sharing and privacy terms are in place with the administrator and partners
Clinical escalation rules are reviewed by qualified clinicians
Available claims data supports later reconciliation
Member communications are reviewed by the plan and its advisor

This page describes an illustrative governance application, not a deployed pathway. Deployment depends on plan-specific applicability, partner capacity, authority and validated workflows. See current product maturity →

Start with the plan’s agreements and available claims.

The Control Tower assessment establishes the plan’s baseline and helps determine which care priorities may warrant governance.